We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
-16.69%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$2.07B
AUM Growth
-$429M
Cap. Flow
+$142M
Cap. Flow %
6.88%
Top 10 Hldgs %
44.14%
Holding
87
New
6
Increased
22
Reduced
12
Closed
8

Top Buys

Rank Stock Value
1
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$137M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$48.1M
3
CNTA
Centessa Pharmaceuticals
CNTA
+$32.9M
4
RPTX
Repare Therapeutics
RPTX
+$28.7M
5
CGEM icon
Cullinan Oncology
CGEM
+$24.3M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$99.7M
2
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$64.9M
3
PTGX icon
Protagonist Therapeutics
PTGX
+$37.2M
4
NGM
NGM Biopharmaceuticals, Inc. Common Stock
NGM
+$14.6M
5
GBIO
Generation Bio
GBIO
+$8.15M

Sector Composition

Rank Sector Weight
1 Healthcare 99.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GBIO
51
DELISTED
Generation Bio
GBIO
$10.3M 0.5%
155,603
-124,692
-44% -$8.15M
PVLA
52
Palvella Therapeutics
PVLA
$2.15B
$9.5M 0.46%
63,504
-3,099
-5% -$565K
PTGX icon
53
Protagonist Therapeutics
PTGX
$8.92B
$8.76M 0.42%
1,106,838
-3,076,381
-74% -$37.2M
SLN
54
Silence Therapeutics
SLN
$549M
$7.9M 0.38%
666,666
– –
PYXS icon
55
Pyxis Oncology
PYXS
$182M
$6.99M 0.34%
2,938,851
+77,000
+3% +$205K
CBIO
56
Crescent Biopharma
CBIO
$555M
$5.71M 0.28%
95,443
– –
ELDN icon
57
Eledon Pharmaceuticals
ELDN
$263M
$5.68M 0.27%
2,326,710
– –
MTEM
58
DELISTED
Molecular Templates, Inc.
MTEM
$4.55M 0.22%
333,104
+63,322
+23% +$1.48M
HLVX
59
DELISTED
HilleVax
HLVX
$4.18M 0.2%
+382,513
New +$4.54M
CLDX icon
60
Celldex Therapeutics
CLDX
$3.02B
$4.15M 0.2%
+154,000
New +$4.47M
INFI
61
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$4.02M 0.19%
6,353,645
– –
IVA
62
Inventiva
IVA
$1.09B
$3.99M 0.19%
686,040
– –
CDTX
63
DELISTED
Cidara Therapeutics
CDTX
$3.35M 0.16%
343,056
– –
ELEV
64
DELISTED
Elevation Oncology
ELEV
$3.24M 0.16%
2,312,200
+2
+0% +$5
MOLN
65
Molecular Partners
MOLN
$147M
$2.98M 0.14%
443,221
– –
SPRO icon
66
Spero Therapeutics
SPRO
$69.5M
$2.29M 0.11%
3,089,615
+1,504,000
+95% +$4.37M
RNAC icon
67
Cartesian Therapeutics
RNAC
$227M
$2.26M 0.11%
57,438
– –
FWP
68
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$2.23M 0.11%
513,791
+80,899
+19% +$431K
LITS
69
Lite Strategy Inc
LITS
$33.6M
$2.14M 0.1%
176,603
– –
PHXM
70
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$1.44M 0.07%
131,466
– –
RNTX
71
Rein Therapeutics
RNTX
$65.7M
$1.37M 0.07%
263,278
– –
CRVS icon
72
Corvus Pharmaceuticals
CRVS
$1.11B
$1.36M 0.07%
1,370,947
– –
GLMD icon
73
Galmed Pharmaceuticals
GLMD
$4.95M
$1.22M 0.06%
9,998
– –
ELTX icon
74
Elicio Therapeutics
ELTX
$76.4M
$1.22M 0.06%
107,130
– –
CALA
75
DELISTED
Calithera Biosciences, Inc
CALA
$1.14M 0.06%
464,742
-4
-0% -$19
1 2
3
4

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q2 2022 Portfolio in Review

As of Q2 2022, BVF Inc held 87 positions worth $2.07B, down 17% from $2.5B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

BVF Inc deployed $142M of net new capital in Q2 2022, opening 6 new positions and adding to 22 existing holdings. Its largest new stake was MoonLake Immunotherapeutics: 21,751,284 shares worth $114M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier.

On the sell side, the largest reduction was Protagonist Therapeutics, an estimated $37.2M trimmed.

  • BVF Inc's largest Q2 2022 buy was MoonLake Immunotherapeutics: 21,751,284 shares worth $114M.
  • BVF Inc added most to Centessa Pharmaceuticals in Q2 2022, an estimated $32.9M increase.
  • BVF Inc's biggest Q2 2022 reduction was Protagonist Therapeutics, cutting an estimated $37.2M.
  • BVF Inc fully exited argenx in Q2 2022, selling an estimated $99.7M.
  • BVF Inc's ten largest holdings make up 44% of its $2.07B portfolio in Q2 2022.
  • BVF Inc opened 6 new positions and closed 8 in Q2 2022.
  • BVF Inc's portfolio value fell 17% quarter-over-quarter to $2.07B.

Based on BVF Inc's 13F filing for Q2 2022, filed 15 Aug 2022.